LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

A Phase 3, Multi-Center, Double-Masked, Vehicle Controlled, Randomized, Parallel-Group Study
to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the
Treatment of Ocular Inflammation and Pain Following Cataract Surgery.

Key Inclusion Criteria:

1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and with
the capacity to provide voluntary informed consent.

2. Be able to read, understand, and provide written informed consent on the Institutional
Review Board (IRB)/Ethics Committee (EC) approved ICF and provide Health Insurance
Portability and Accountability Act (HIPAA) authorization.

3. Be willing and able to comply with all treatment and follow-up/study procedures.

4. Be a candidate for routine, uncomplicated cataract surgery (phaco-emulsification with
posterior chamber intraocular lens [IOL] implantation, not combined with any other
surgery).

5. In the Investigator's opinion, have potential postoperative pin-holed Snellen visual
acuity (VA) of at least 20/200 in the study eye at Visit 1 (Screening) and at least
20/200 in the fellow eye.

Key Exclusion Criteria:

1. Have a severe/serious ocular condition or history/presence of chronic generalized
systemic disease that the Investigator feels might increase the risk to the subject or
confound the result(s) of the study.

2. Be a female subject who is pregnant or breastfeeding.

3. Be monocular (fellow eye is nonfunctional or fellow eye's pinhole vision is worse than
Snellen 20/200).

4. Have had ocular surgery (including laser surgery) in the study eye within 3 months or
in the fellow eye within 2 weeks prior to Visit 1 (Screening).